Related Experiment Video
Updated: Jul 9, 2026

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
Published on: August 2, 2021
dDual-target rTMS treatment for adolescent depression with headache: a case report
Guangwei Sun1, Yingying Yin2, Yonggui Yuan1
1Department of Psychiatry and Psychosomatics, Zhongda Hospital, School of Medicine, Jiangsu Provincial Key Laboratory of Brain Science and Medicine, Southeast University, No. 87 Dingjiaqiao Road, Nanjing, 210009, China.
Repetitive transcranial magnetic stimulation (rTMS) may effectively treat adolescents with co-occurring major depressive disorder and headache. A dual-target rTMS protocol showed significant symptom improvement in a 16-year-old patient.
Area of Science:
- Neuroscience
- Psychiatry
- Pain Management
Background:
- Major depressive disorder (MDD) in adolescents often co-occurs with headache, causing significant impairment.
- Limited evidence exists for combined affect and pain network targeting in these comorbid cases.
Purpose of the Study:
- To investigate the feasibility of a dual-target repetitive transcranial magnetic stimulation (rTMS) protocol for adolescent MDD with comorbid headache.
Main Methods:
- A 16-year-old male with a 2-year history of depression and headache received a dual-target rTMS protocol.
- Treatment involved targeting the dorsolateral prefrontal cortex and primary motor cortex over 2 weeks (40 sessions).
Main Results:
- The patient experienced significant improvement in both depressive and headache symptoms after the 2-week rTMS treatment.
- The dual-target approach demonstrated potential efficacy in managing comorbid symptoms.
Conclusions:
- An intensified dual-target rTMS protocol may be a feasible treatment option for adolescents with comorbid depression and headache.
- Further prospective studies are required to confirm optimal parameters, long-term effects, and safety.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Electroconvulsive Therapy
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

